RESPONSE ONCOLOGY INC 

$0.000001
2
+$0.00+0% Tuesday 15:30

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
12.18
P/E Ratio
0
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.42B
Vertex Pharmaceuticals focuses on developing and commercializing therapies for cancer and other serious diseases, directly competing in the oncology market.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol-Myers Squibb is a major player in the oncology sector, developing numerous drugs for various types of cancer, overlapping with Response Oncology's market.
Merck
MRK
Mkt Cap370.89B
Merck is known for its strong portfolio in cancer treatment, including immunotherapy drugs that compete in the same space as Response Oncology's offerings.
Pfizer
PFE
Mkt Cap162.16B
Pfizer has a broad range of cancer treatments, including therapies for breast and lung cancer, competing with Response Oncology's cancer care solutions.
Novartis
NVS
Mkt Cap304.1B
Novartis offers targeted cancer therapies and has a significant presence in the oncology market, making it a direct competitor.
AMGEN
AMGN
Mkt Cap236.38B
Amgen specializes in human therapeutics, including treatments for cancer, which pits it against Response Oncology in the oncology treatment market.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences, known for its innovations in medicine, also has a growing focus on oncology, competing with Response Oncology's cancer therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.22B
Regeneron Pharmaceuticals is involved in developing and commercializing products for treating cancer, directly competing with Response Oncology.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a strong pipeline in oncology, including therapies for various cancers, which competes with Response Oncology's products.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its pharmaceutical division, develops treatments for several types of cancer, competing in the same space as Response Oncology.

About

Medical/Nursing Services
Health Services
Health Care and Social Assistance
Offices of Physicians (except Mental Health Specialists)
Response Oncology, Inc. does not have significant operations. The company, along its wholly owned and majority owned subsidiaries, operated as a comprehensive cancer management company. As of May 20, 2002, the company has liquidated substantially all of its operating assets and anticipates that the remaining assets would be liquidated and all wind-down activities completed by the end of 2002. Prior to the sale of its assets, it provided: advanced cancer treatment services through outpatient facilities known as IMPACT Centers under the direction of practicing oncologists; owned the assets of and managed the nonmedical aspects of oncology practices; compounded and dispensed pharmaceuticals to certain oncologists for a fixed or cost plus fee; and conducted outcomes research on behalf of pharmaceutical manufacturers. The company was incorporated in 1984 and is based in Memphis, Tennessee.
Show more...
CEO
Employees
10
Country
United States

Listings

0 Comments

Share your thoughts

FAQ

What is RESPONSE ONCOLOGY INC stock price today?
The current price of ROIX is $0.00 USD — it has increased by +0% in the past 24 hours. Watch RESPONSE ONCOLOGY INC stock price performance more closely on the chart.
What is RESPONSE ONCOLOGY INC stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on OTC MARKETS exchange RESPONSE ONCOLOGY INC stocks are traded under the ticker ROIX.
What is RESPONSE ONCOLOGY INC market cap?
Today RESPONSE ONCOLOGY INC has the market capitalization of 12.18
How many employees does RESPONSE ONCOLOGY INC have?
As of September 09, 2026, the company has 10 employees.
In which sector is RESPONSE ONCOLOGY INC located?
RESPONSE ONCOLOGY INC operates in the Health & Wellness sector.
When did RESPONSE ONCOLOGY INC complete a stock split?
RESPONSE ONCOLOGY INC has not had any recent stock splits.